Open an account

Prothena

PRTA · NASDAQ

$8.50+$0.02 (+0.24%)TodayMarket closed ·
Prev close $8.48

About PRTA

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Employees
67
Headquarters
DUBLIN
Listed
Dec 21, 2012
Sector
Health Care
Industry
Biotechnology
Website
prothena.com

PRTA key statistics

Market cap
436.36M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
550.20K
Volume
529.08K
Open price
$8.55
High today
$8.65
Low today
$8.45
52 Week high
$11.80
52 Week low
$7.73

Prothena (PRTA) at a glance

Prothena (PRTA) last traded at $8.50, with a market cap of 436.36M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.45 and $8.65. The current price is 0.6% above the day's low and 1.7% below its high.

Volume so far is 529.08K shares, in line with the average of 550.20K shares a day.

Over the past year Prothena has ranged from $7.73 to $11.80, and now sits 19% of the way up that range.

Prothena met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.36 per share against an estimate of -$0.3988.

The average analyst price target is $21.83, 156.8% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 7 analystsAvg $21.83
Low
$8.08
Now
$8.50
High
$37.80

PRTA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 64.5% on average.

  1. Q3 FY24: reported -$1.10 per share against an estimate of -$1.20
  2. Q4 FY24: reported -$1.08 per share against an estimate of -$1.06
  3. Q1 FY25: reported -$1.12 per share against an estimate of -$0.9928
  4. Q2 FY25: reported -$1.73 per share against an estimate of -$1.34
  5. Q3 FY25: reported -$0.68 per share against an estimate of -$0.7009
  6. Q4 FY25: reported -$0.40 per share against an estimate of -$0.57
  7. Q1 FY26: reported $0.61 per share against an estimate of -$0.3553
  8. Q2 FY26: reported -$0.36 per share against an estimate of -$0.3988

PRTA news

  • Press releaseBusiness Wire

    Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseBusiness Wire

    Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

  • Press releaseBusiness Wire

    Prothena to Report Second Quarter 2026 Financial Results on August 6

  • Press releaseBusiness Wire

    Prothena Reports First Quarter 2026 Financial Results and Business Highlights

  • Press releaseBusiness Wire

    Prothena to Report First Quarter 2026 Financial Results on May 7

  • Press releaseBusiness Wire

    Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

  • Press releaseBusiness Wire

    Prothena Announces Leadership Team Updates

  • Press releaseBusiness Wire

    Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Similar companies

Companies in the same industry as Prothena

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.